Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05478278 · ClinicalTrials.gov registry record · Phase 1
An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics
A Phase 1 study, sponsored by Usona Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT05478278 is a Phase 1 study that has completed, run by Usona Institute. The registered enrollment target is 60 participants.
The verdict
NCT05478278, a Phase 1 study, has completed, sponsored by Usona Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study is comprised of two parts. The purpose of the first part of this study is to evaluate the effects of a supratherapeutic dose of psilocybin on cardiac repolarization. The purpose of the second part of the study is to evaluate the effects of food on the pharmacokinetics of psilocybin.
Interventions
- DRUG Psilocybin
- DRUG Moxifloxacin
- DRUG Micro-Crystalline Cellulose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-06-22 |
| Est. Completion | 2023-08-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05478278
The ClinicalTrials.gov registry entry for NCT05478278 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Usona Institute, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Psilocybin is the first listed.
NCT05478278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05478278 about?
NCT05478278 is a clinical study titled "An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics". This study is comprised of two parts. The purpose of the first part of this study is to evaluate the effects of a supratherapeutic dose of psilocybin on cardiac repolarization. The purpose of the second part of the study is to evaluate the effects of food on the pharmacokinetics of psilocybin.
What is the current status of trial NCT05478278?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2022-06-22. Estimated completion is 2023-08-09.
What interventions are being tested in trial NCT05478278?
The interventions under investigation include: Psilocybin (DRUG), Moxifloxacin (DRUG), Micro-Crystalline Cellulose (DRUG).
Who is sponsoring clinical trial NCT05478278?
This trial is sponsored by Usona Institute, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.